Basilea Bids Farewell To Oncology To Focus On Anti-Infectives
Puts Faith In US Approval Of Antibiotic Zevtera
Executive Summary
Derazantinib, a promising fibroblast growth factor kinase inhibitor, is one of the cancer assets the Swiss firm is preparing to sell off, either separately or in a bundle, as it focuses on anti-infectives.
You may also be interested in...
Stock Watch: Defeat Is The Mother Of Reinvention
Companies that are successful do not need to change their name, therapeutic area or product focus.
Can Basilea’s Antibiotic Succeed Where Others Have Failed?
The Swiss biotech says the ERADICATE trial shows areas of differentiation for the antibiotic, like utility in pneumonia and across gram-negative and gram-positive bacteria.
Basilea Stresses Derazantinib's FGFR Kinase Differentiation
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.